Therapy News and Research

RSS

EphA4 receptor may be promising target for future ALS drug

Leuven scientists (VIB/KU Leuven) are using zebrafish as a model in their search for genes that play a role in the mechanism of amyotrophic lateral sclerosis (ALS). As a result, they have identified a molecule that could be the target for a future ALS treatment.

28 Aug 2012

Renal denervation regenerates blood vessels and could reduce cardiovascular events

Renal denervation improves blood pressure and arterial stiffness in patients with therapy resistant hypertension, according to research presented at ESC Congress 2012 by Mr Klaas Franzen from the University Hospital of Schleswig-Holstein.

28 Aug 2012

Patients with severe aortic stenosis can profit from TAVI procedure

Transcatheter aortic valve implantation (TAVI) leads to meaningful improvements in health-related quality of life in patients with severe aortic stenosis that are maintained for at least 1 year, according to a study presented at ESC Congress 2012.

28 Aug 2012

Control of siRNA could aid regenerative medicine, cancer therapy

Some of the body's own genetic material, known as small interfering RNA (siRNA), can be packaged then unleashed as a precise and persistent technology to guide cell behavior, researchers at Case Western Reserve University report in the current issue of the journal, Acta Biomaterialia.

28 Aug 2012

Spinal cord stimulation could become novel treatment option for heart failure

Spinal cord stimulation improves heart function and could become a novel treatment option for heart failure, according to research presented at the ESC Congress 2012 today, August 25, by Professor Hung-Fat Tse from Hong Kong.

28 Aug 2012

Personalized antiplatelet treatment leads to better outcomes in patients undergoing PCI

Personalized antiplatelet treatment leads to better outcomes than standard antiplatelet treatment in patients undergoing coronary stent implantation, according to results from the MADONNA study presented at ESC Congress 2012.

28 Aug 2012

Leg compressions after stroke appear to trigger natural protective mechanisms that reduce damage

Successive, vigorous bouts of leg compressions following a stroke appear to trigger natural protective mechanisms that reduce damage, researchers report.

28 Aug 2012

America Stem Cell commences ASC-101 Phase I/II study in hematologic malignancies

America Stem Cell, Inc. announced today the initiation of a single-center study at The University of Texas MD Anderson Cancer Center evaluating ASC-101 in dual-umbilical cord transplantation in patients with hematologic malignancies.

28 Aug 2012

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.

28 Aug 2012

Diaverum plans to increase peritoneal dialysis use among patients with ESRD

Diaverum, one of the world's leading renal care providers, is planning to give more patients the possibility to be treated with peritoneal dialysis to increase their quality of life.

27 Aug 2012

Insulin glargine retards progression of atherosclerosis in high-risk people

A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.

27 Aug 2012

Renal denervation leads to better outcomes than standard drug treatment in patients with AHF

Renal denervation leads to better outcomes than standard drug treatment in patients with advanced heart failure, according to research presented at ESC Congress 2012. The results of the Olomouc I pilot study were presented by Dr Miloš Táborský from the University Hospital Olomouc.

27 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

27 Aug 2012

Spironolactone should be considered as a treatment option in hypertensive patients with DHF

Mineralocorticoid receptor antagonists should be considered as a treatment option in hypertensive patients with diastolic heart failure, said Professor Burkert Pieske presenting results today of the Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) study at ESC Congress 2012.

27 Aug 2012

Baylor Plano first hospital to merge MEM software and Epoch platform for atrial fibrillation therapy

Baylor Plano became the first hospital in the world on Friday to merge two highly advanced technologies for atrial fibrillation therapy.

27 Aug 2012

IABP does not improve blood pressure symptoms in patients with cardiogenic shock

A balloon pump inserted in the aorta is currently the most widely used support device in the treatment of cardiogenic shock and, since its introduction in 1968, has been used in several million people.

27 Aug 2012

Renal denervation safe and effective in patients with treatment resistant hypertension

Renal denervation leads to significant and sustained blood pressure reduction for up to 18 months in patients with treatment resistant hypertension, according to research presented at ESC Congress 2012.

27 Aug 2012

Debiopharm initiates enrollment in triptorelin phase III study for central precocious puberty

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced that the first patient has been enrolled in an open-label phase III study to investigate the efficacy, safety, and pharmacokinetics of the sustained release triptorelin pamoate 22.5 mg 6-month-formulation in children with central precocious puberty (CPP), a rare disease.

27 Aug 2012

Obesity at diagnosis of breast cancer associated with increased risk of recurrence

Extra pounds-even within the overweight but not obese range-are linked to a higher risk of recurrence of the most common type of breast cancer despite optimal cancer treatment, according to a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

27 Aug 2012

Therapy News and Research

EphA4 receptor may be promising target for future ALS drug

Renal denervation regenerates blood vessels and could reduce cardiovascular events

Patients with severe aortic stenosis can profit from TAVI procedure

Control of siRNA could aid regenerative medicine, cancer therapy

Spinal cord stimulation could become novel treatment option for heart failure

Personalized antiplatelet treatment leads to better outcomes in patients undergoing PCI

Leg compressions after stroke appear to trigger natural protective mechanisms that reduce damage

America Stem Cell commences ASC-101 Phase I/II study in hematologic malignancies

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Diaverum plans to increase peritoneal dialysis use among patients with ESRD

Insulin glargine retards progression of atherosclerosis in high-risk people

Renal denervation leads to better outcomes than standard drug treatment in patients with AHF

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Spironolactone should be considered as a treatment option in hypertensive patients with DHF

Baylor Plano first hospital to merge MEM software and Epoch platform for atrial fibrillation therapy

IABP does not improve blood pressure symptoms in patients with cardiogenic shock

Renal denervation safe and effective in patients with treatment resistant hypertension

Debiopharm initiates enrollment in triptorelin phase III study for central precocious puberty

Obesity at diagnosis of breast cancer associated with increased risk of recurrence

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News